The Shifting ATTR-CM Landscape: Early Diagnosis, Emerging Therapies & Personalized Care
- Author
- ReachMD
- Published
- Fri 13 Dec 2024
- Episode Link
- http://reachmd.com/programs/cme/the-shifting-attr-cm-landscape-early-diagnosis-emerging-therapies-personalized-care/27090/
CME credits: 0.50
Valid until: 13-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-shifting-attr-cm-landscape-early-diagnosis-emerging-therapies-personalized-care/27090/
Valid until: 13-12-2025
Claim your CME credit at https://reachmd.com/programs/cme/the-shifting-attr-cm-landscape-early-diagnosis-emerging-therapies-personalized-care/27090/
Achieving optimal outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) remains a challenge as diagnosis is often delayed. Patients have a reduced life expectancy and experience debilitating pain and poor quality of life. Hear from the experts as they review the latest information on new and emerging treatment options for transthyretin amyloidosis and how this condition affects patients with cardiomyopathy.
=